Pulse Biosciences, INC 10-Q quarterly reports

Pulse Biosciences, Inc. reported its Q2 2026 results, highlighting progress in cardiac device development while continuing to incur significant operating losses and relying on equity financing.

Pulse Biosciences reports first product revenue in Q1 2026, driven by Vybrance System, while advancing cardiac programs and managing operational expenses.

Pulse Biosciences reported increased net losses in Q3 2025 as it ramps up R&D and commercialization efforts for its NPS technology, securing first product revenue.

Pulse Biosciences reported a significant increase in net loss for Q2 2025 and H1 2025, driven by higher research and development and general and administrative expenses, despite advancing its novel nsPFA technology in cardiology and soft tissue ablation.

Pulse Biosciences reports a net loss of $16.8 million for Q1 2025, focusing on advancing its Nano-pulse Stimulation (NPS) technology in cardiology and soft tissue ablation.

Pulse Biosciences reports its Q3 2024 financial results, emphasizing advancements in its atrial fibrillation and soft tissue ablation programs, while continuing to operate without significant revenue.

Pulse Biosciences' Q2 2024 report highlights a continued focus on developing its nsPFA technology for atrial fibrillation and soft tissue ablation, with no revenue reported and ongoing operating losses.

Pulse Biosciences reported its first quarter 2024 results, highlighting a continued focus on developing its Nano-pulse Stimulation technology for atrial fibrillation treatment and other medical applications.